Severe Hemophilia A Clinical Trials

37 clinical trials for Severe Hemophilia A across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment. — RECRUITING · PHASE3
• Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment — RECRUITING · PHASE3
• A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. — RECRUITING · PHASE1
• Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study — RECRUITING · PHASE4
• Palliative Care Needs of Children With Rare Diseases and Their Families — RECRUITING · NA
• Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein — RECRUITING · PHASE3
• Dynamics of the Anti-factor VIII Antibody Signature During Treatment With Emicizumab — RECRUITING
• Randomized, active-controlled, double-blind, parallel design study to evaluate the efficacy and safety of a once-a-week prophylaxis treatment with BAY 79-4980 compared to three times-per-week prophylaxis with rFVIII-FS in previously treated patients with severe hemophilia A — COMPLETED · PHASE2
• A phase II/III, randomized, cross-over, open-label trial to demonstrate superiority of prophylaxis over on-demand therapy in previously treated subjects with severe hemophilia A treated with plasma protein-free recombinant FVIII formulated with sucrose (BAY 81-8973) — COMPLETED · PHASE3
• Study to Investigate the product Wilate in Patients aged 1 to 11 years with Severe Hemophilia A — OTHER · PHASE3
• A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis — ACTIVE_NOT_RECRUITING · PHASE4
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors — ACTIVE_NOT_RECRUITING · PHASE3
• To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A — ACTIVE_NOT_RECRUITING · PHASE1
• Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A — TERMINATED · PHASE1
• Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A — COMPLETED · PHASE4
• (21824) A phase 3, single group treatment, open-label study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe hemophilia A — OTHER · PHASE3
• Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia A — NOT_YET_RECRUITING · PHASE3
• Bone Microarchitecture in Men With Hemophilia — TERMINATED · NA
• rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study — COMPLETED · PHASE3
• A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection — COMPLETED · PHASE1
• A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection — COMPLETED · PHASE2
• An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A — COMPLETED · PHASE3
• Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) — COMPLETED · NA
• Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A — COMPLETED · PHASE3
• Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII — COMPLETED · PHASE3
• Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A — COMPLETED · PHASE3
• Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients — COMPLETED · PHASE3
• Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A — COMPLETED · PHASE3
• Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A — COMPLETED · PHASE1
• Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale — COMPLETED · PHASE3
• Pharmacokinetics of rFVIIIFc at Two Vial Strengths — COMPLETED · PHASE1
• Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive — WITHDRAWN · NA
• Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs) — COMPLETED · PHASE3
• Canadian Hemophilia Prophylaxis Study — COMPLETED · PHASE4
• Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform — WITHDRAWN · PHASE3
• Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A — COMPLETED · PHASE3
• Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A — TERMINATED · PHASE3

Refine this search